Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Approved World’s 1st Topical JAK Inhibitor Delgocitinib, and More
January 24, 2020
- PMDA to Provide Information Free of Charge for Drug Makers to Consider Use of MID-NET Starting in April
January 24, 2020
- Chuikyo OKs New Drug Pricing Rules for 2020 Reform
January 23, 2020
- Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
- Get Serious about Reviewing Scope of Health Coverage, Says MOF Budget Examiner
January 22, 2020
- Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020
- MHLW Orders Label Revisions for Suglat, Sujanu, and More
January 22, 2020
- Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash
January 21, 2020
- MHLW Bureau Chief Urges Prefectural Officials to Up Monitoring Efforts after GMP Lapses Found
January 21, 2020
- MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues
January 17, 2020
- Takeda’s RCC Drug Cabometyx in MHLW Panel’s Review Roster for January 29; Alecensa, Opdivo and More
January 16, 2020
- Japan Forgoes Creation of Medical Fee to Reward Hospital Formularies in 2020 Reform
January 16, 2020
- HIV Meds Dovato, Pifeltro to Join NHI Price List on January 22
January 16, 2020
- Australia to Provide Expedited Reviews for OTC and Quasi-Drugs Approved in Japan
January 16, 2020
- Rotavirus Vaccine to Be Included in Public Vaccination Programs Starting Oct. 1
January 16, 2020
- Novartis’ Eylea Contender Up for MHLW Panel Review on January 27
January 15, 2020
- Japan Approves 2 HIV Drugs, Listing Expected Soon
January 15, 2020
- Japan Likely to Take Pass on Rewarding Formulary Initiatives under Medical Fee Schedule
January 14, 2020
- Osaka Univ. Professor, Mitsubishi Tanabe Receive Prime Minister’s R&D Award for Contributions to Development of SGLT2 Inhibitor
January 14, 2020
- MHLW to Beef Up GMP Inspections at API Manufacturing Sites in Asia from FY2020 in Response to Series of Supply Disruptions
January 6, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…